Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Research output: Contribution to journalJournal articleResearchpeer-review

  • Antonio Palumbo
  • Roman Hajek
  • Michel Delforge
  • Martin Kropff
  • Maria Teresa Petrucci
  • John Catalano
  • Heinz Gisslinger
  • Wiesław Wiktor-Jędrzejczak
  • Mamia Zodelava
  • Katja Weisel
  • Nicola Cascavilla
  • Genadi Iosava
  • Michele Cavo
  • Janusz Kloczko
  • Joan Bladé
  • Meral Beksac
  • Ivan Spicka
  • Torben Plesner
  • Joergen Radke
  • Christian Langer
  • Dina Ben Yehuda
  • Alessandro Corso
  • Lindsay Herbein
  • Zhinuan Yu
  • Jay Mei
  • Christian Jacques
  • Meletios A Dimopoulos
  • MM-015 Investigators

View graph of relations

Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.
JournalThe New England Journal of Medicine
Issue number19
Pages (from-to)1759-69
Publication statusPublished - 2012

    Research areas

  • Administration, Oral, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Melphalan, Multiple Myeloma, Neoplasms, Second Primary, Neutropenia, Prednisone, Thalidomide